SEC Form 4 · accession 0001104659-19-002512
Rubius Therapeutics, Inc. · RUBY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Langer
Director
Period of report
Jan 14, 2019
Accepted (ET)
Jan 18, 2019 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001709401
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 14, 2019 | M | 7,500 | $0.15 | A | 7,500 | D | |
| Common StockF2 | Jan 14, 2019 | S | 7,500 | $14.5925 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.15 | Jan 14, 2019 | M | 7,500 | D | — | Feb 4, 2025 | Common Stock | 7,500 | 142,500 | D |
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $15.02, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F325% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter.